Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.

Journal of viral hepatitis - 1 Jan 2013

Tedder R S, Tuke P, Wallis N, Wright M, Nicholson L, Grant P R

Abstract excerpt

During viral assembly, viral proteins are released into plasma and can be used to infer viral load. The Architect hepatitis C virus (HCV) core antigen (Ag) assay is a potential alternative to HCV RNA quantification for measuring response to therapy and predicting an end of treatment viral response (EOTR). The HCVp22Ag assay was used to infer viral load in 68 window RNA-containing samples and in 284 samples from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C
Share to Hepatitis C Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Kaplan-Meier Estimate

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Core Proteins

Source

Identifiers

PMID: 23231086
DOI: 10.1111/j.1365-2893.2012.01630.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.PMID 23231086Read ↗

Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.Semantic proximity Read ↗

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.Semantic proximity Read ↗

Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs.Semantic proximity Read ↗

Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.Semantic proximity Read ↗

Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.Semantic proximity Read ↗

Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response.Semantic proximity Read ↗

Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients.Semantic proximity Read ↗

Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.Semantic proximity Read ↗

Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?Semantic proximity Read ↗

Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay.Semantic proximity Read ↗

[Evaluation of ARCHITECT HCV core antigen assay].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.